Date:11/15/2010

such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

'/>"/>

SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
2. FDA Approves New Indication for Afinitor
3. FDA Approves Teflaro for Bacterial Infections
4. FDA Approves Latuda to Treat Schizophrenia in Adults
5. FDA Approves Additional Medical Indication for Sprycel
6. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
7. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
8. FDA Approves Botox to Treat Chronic Migraine
9. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
10. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
11. FDA Approves Combination Contraceptive Containing a Folate